Sino Biological, Inc. (SZSE: 301047) has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research.
Early reports that Omicron causes less-severe disease than Delta seem to be borne out, but it’s not yet clear to what extent that’s due to the variant itself versus the populations it’s infecting.